Glenmark stock gained 0.70 percent after US acne launch

Published on 10/07/2026 at 00:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Glenmark stock moved to INR 2,311 on October 6, 2026, while a US pump-pack launch targets a USD 45.8 million market. Q1 FY27 revenue rose 23.1 percent.

Glenmark, INE935A01035, Illustration mit AI erstellt.

Glenmark Pharmaceuticals stock (ISIN INE935A01035) gained 0.70 percent to INR 2,311 on the NSE on October 6, 2026, as its US subsidiary launched Adapalene Gel USP 0.1% in pump packs. The product targets a USD 45.8 million annual market segment, according to ScanX.

US dermatology gets a new format

ScanX reported that Glenmark Therapeutics USA introduced the over-the-counter product on October 6, 2026, as a therapeutic equivalent to the active ingredient in Differin Gel. The launch expands Glenmark's US dermatology portfolio through a packaging change rather than a new molecule approval.

The commercial importance is incremental but measurable. Glenmark is entering an established market segment with annual sales of USD 45.8 million, while the pump format gives the company a product-level differentiation point in a competitive generic market.

Q1 growth sets the operating base

Glenmark reported consolidated Q1 FY27 revenue of INR 4,018.5 crore, up 23.1 percent year over year, while EBITDA rose 38.6 percent to INR 804.8 crore. The figures come from Sahi, which also reported profit after tax of INR 482.8 crore for the quarter ended June 30, 2026.

The earlier quarter provides the key comparison. EBITDA margin reached 20.03 percent in Q1 FY27, while North America revenue increased 41.1 percent year over year to INR 1,097.4 crore, including deferred licensing income, according to DSIJ.

Consensus target stays above the price

The analyst consensus was Buy from 11 analysts, with 10 Buy ratings, 2 Hold ratings and 0 Sell ratings. Investing.com listed an average 12-month target of INR 2,497.73, with a high of INR 2,750 and a low of INR 2,100. The average price target lies 8.09 percent above the NSE price of INR 2,311 on October 6, 2026.

Motilal Oswal's Buy recommendation carried a target of INR 2,570 in an August 3, 2026 update, as reported by DSIJ. The same research highlighted higher input and freight costs, as well as greater research and development spending, as factors that could pressure earnings.

Glenmark stock remains below its yearly high

Glenmark stock was last at INR 2,311 on the NSE at 3:15 p.m. IST on October 6, 2026, with a daily gain of 0.70 percent. Its 52-week range was INR 1,792.60 to INR 2,537.60, while market capitalization stood at INR 652.2 billion.